RICHARD D. PEARSON, M.D.; ERIK L. HEWLETT, M.D.
Niclosamide [N-(2′-chloro-4′-nitrophenyl)-5-chlorosalicylamide] was developed at Bayer A. G. (1-3) and initially shown to be effective against Hymenolepis diminuta, the rat tapeworm, a cestode that occasionally infects humans. Subsequent studies in animals and humans showed that niclosamide was poorly absorbed and non-toxic after oral administration (2) and that it was active against a number of tapeworms that infect humans. Niclosamide is also used in veterinary practices and as a molluscicide.
Niclosamide first became commercially available outside the United States in 1961 (Yomesan; Bayer A.G., Wuppertal, West Germany), but until recently it could be obtained in this country only as an investigational
Learn more about subscription options.
Register Now for a free account.
PEARSON RD, HEWLETT EL. Niclosamide Therapy for Tapeworm Infections. Ann Intern Med. 1985;102:550–551. doi: 10.7326/0003-4819-102-4-550
Download citation file:
Published: Ann Intern Med. 1985;102(4):550-551.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only